ArticleRheumatology (Oxford, England)2025
Frequency-specific microcurrent improves hand function and Raynaud's symptoms in scleroderma: results of two pilot studies.
Article in Rheumatology (Oxford, England), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectivesTo evaluate the efficacy of frequency-specific microcurrent as a treatment designed to improve hand function and alleviate Raynaud's symptoms in patients with systemic sclerosis.
methodsSeventeen patients were treated in two separate pilot studies for 60 and 45 min, respectively, over 1 or 2 days with microcurrent frequencies specific to scarring in the hands and capillaries, and to Raynaud's disease. Efficacy was evaluated using the Cochin hand function score questionnaire before and after treatment, and a visual analogue scale to evaluate the severity of the Raynaud's symptoms.
resultsImprovement in hand function was observed in both studies, being significant in the second pilot study with an average improvement of 38% (95% CI 22%-55%, P = 0.002) and in both studies combined with an average improvement of 40% (95% CI 26%-55%, P = 0.0001). There was a significant improvement in mean Raynaud's VAS scores pre- and post-treatment of 18 points (out of 100), 95% CI 3.3-33 points, P = 0.016. A proportion of patients achieved very substantial improvements in hand function, with particular tasks improving from being nearly impossible to do to being able to be performed without difficulty.
conclusionsThe degree of improvement in hand function obtained over a very short treatment period of 45 min to 1 h was significant. Further randomized, controlled studies are needed to confirm these results, and longer-term follow-up will be required to establish whether the changes are maintained and whether repeated treatments can produce further improvements.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.